Evolution of NCEP guidelines: ATP1-ATPIII risk estimation for coronary heart disease in 2002. National Cholesterol Education Program.
作者信息
Conti C Richard
出版信息
Clin Cardiol. 2002 Mar;25(3):89-90. doi: 10.1002/clc.4960250302.
Abstract
摘要
相似文献
1
Evolution of NCEP guidelines: ATP1-ATPIII risk estimation for coronary heart disease in 2002. National Cholesterol Education Program.
Clin Cardiol. 2002 Mar;25(3):89-90. doi: 10.1002/clc.4960250302.
2
New guidelines for blood cholesterol by the National Cholesterol Education Program (NCEP). National Cholesterol Education Program (NCEP).
Prog Cardiovasc Nurs. 1994 Winter;9(1):43-4.
3
Update on managing hypercholesterolemia. The new NCEP guidelines.
AAOHN J. 2002 Aug;50(8):360-4.
4
Improving the prediction of coronary heart disease to aid in the management of high cholesterol levels: what a difference a decade makes.
JAMA. 1998 Feb 11;279(6):445-9. doi: 10.1001/jama.279.6.445.
5
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).
JAMA. 2001 May 16;285(19):2486-97. doi: 10.1001/jama.285.19.2486.
6
7
Revised guidelines for the treatment of elevated cholesterol levels in adults: a prime role for secondary prevention.
Coron Artery Dis. 1994 Feb;5(2):175-7. doi: 10.1097/00019501-199402000-00012.
8
Impact of the new National Cholesterol Education Program (NCEP) guidelines on patient management.
J Am Acad Nurse Pract. 2003 Aug;15(8):350-60. doi: 10.1111/j.1745-7599.2003.tb00408.x.
9
Achieving National Cholesterol Education Program goals for low-density lipoprotein cholesterol in cardiac patients: importance of diet, exercise, weight control, and drug therapy.
Mayo Clin Proc. 1999 May;74(5):466-73. doi: 10.4065/74.5.466.
10
National cholesterol education program (NCEP) guidelines too complex.
Prev Cardiol. 2005 Summer;8(3):188. doi: 10.1111/j.1520-037x.2005.4358.x.
引用本文的文献
1
Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9.
AAPS J. 2015 Jul;17(4):881-90. doi: 10.1208/s12248-015-9750-8. Epub 2015 Mar 31.
2
Journey in guidelines for lipid management: From adult treatment panel (ATP)-I to ATP-III and what to expect in ATP-IV.
Indian J Endocrinol Metab. 2013 Jul;17(4):628-35. doi: 10.4103/2230-8210.113753.
3
Evaluation of cardiovascular risk in blood donors: results of the CARDIORISK study in the Parma Transfusion Service.
Blood Transfus. 2010 Jul;8(3):155-8. doi: 10.2450/2009.0097-09.
Zotero 插件